Zacks Investment Research downgraded shares of EPOCRATES INC (EPOC) from NEUTRAL to UNDERPERFORM on December 06, 2012, with a target price of $9.20.
Epocrates Inc. provides mobile drug reference tools to healthcare professionals and interactive services to the healthcare industry on all major U.S. mobile platforms including Apple (iPhone, iPod touch and iPad), Android, BlackBerry, Palm and Windows Mobile devices. Services offered by the Company include DocAlert clinical messages that deliver product news and alerts to healthcare professionals. Its Virtual Representative Services includes drug detailing, sampling and patient literature delivery. Epocrates Inc. has offices in California and New Jersey.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on EPOCRATES INC (EPOC),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment